Barry Ticho sold $178k of STOK
CHIEF MEDICAL OFFICER at Stoke Therapeutics, Inc.. 13,945 shares at an average of $12.78, traded Dec 6, 2024, filed Dec 10, 2024.
Score components
- +15RoleOfficer
- +12Trade size$178k at market
- +5Share of holdings soldSold 23% of holdings
- +15Cluster3 insiders selling within 14 days
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -32.4%, 3m -38.2%, 6m -14.3%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001415889-24-028892, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Dec 6, 2024 | SOpen-market sale Common Stock | -13,945 | $12.78 | $178k | 47,332 | Dec 10, 2024 |
Related signals
Other insiders at Stoke Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 3Weak | Stoke Therapeutics, Inc. | Jonathan Allan GENERAL COUNSEL & CORP SEC | $17k 627 shares | -3% | |
| 8Weak | Stoke Therapeutics, Inc. | Barry Ticho CHIEF MEDICAL OFFICER | $27k 1,051 shares | -5% | |
| 11Weak | Stoke Therapeutics, Inc. | Barry Ticho CHIEF MEDICAL OFFICER | $170k 5,545 shares | -22% | |
| 34Weak | Stoke Therapeutics, Inc. | Jonathan Allan GENERAL COUNSEL & CORP SEC | $313k 9,293 shares | -32% | |
| 49Moderate | Stoke Therapeutics, Inc. | Jonathan Allan GENERAL COUNSEL & CORP SEC | $286k 8,895 shares | -24% | |
| 50Moderate | Stoke Therapeutics, Inc. | Jason Hoitt Chief Patient Officer | $119k 3,712 shares | -27% | |
| 58Moderate | Stoke Therapeutics, Inc. | Thomas Leggett Chief Financial Officer | $147k 4,578 shares | -31% | |
| 15Weak | Stoke Therapeutics, Inc. | Arthur A Levin director | $22k 605 shares | -12% | |
| 40Moderate | Stoke Therapeutics, Inc. | Adrian R. Krainer director | $1.3M 33,243 shares | -11% | |
| 17Weak | Stoke Therapeutics, Inc. | Adrian R. Krainer director | $287k 7,229 shares | -2% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.